Literature DB >> 11723300

Possible efficacy of temozolomide in a patient with gliomatosis cerebri.

A Benjelloun1, J Delavelle, F Lazeyras, P Y Dietrich.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11723300     DOI: 10.1212/wnl.57.10.1932

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


× No keyword cloud information.
  6 in total

1.  Gliomatosis cerebri: a review of 296 cases from the ANOCEF database and the literature.

Authors:  Sophie Taillibert; Catherine Chodkiewicz; Florence Laigle-Donadey; Massimo Napolitano; Stéphanie Cartalat-Carel; Marc Sanson
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

Review 2.  Gliomatosis cerebri in young patients' report of three cases and review of the literature.

Authors:  Alessandro Landi; Manolo Piccirilli; Cristina Mancarella; Felice Giangaspero; Maurizio Salvati
Journal:  Childs Nerv Syst       Date:  2010-04-08       Impact factor: 1.475

3.  Gliomatosis cerebri in children. Case report and clinical considerations.

Authors:  Emanuela Caroli; Epimenio Ramundo Orlando; Luigi Ferrante
Journal:  Childs Nerv Syst       Date:  2005-01-27       Impact factor: 1.475

4.  Prognostic factors for patients with gliomatosis cerebri: retrospective analysis of 17 consecutive cases.

Authors:  Tomoo Inoue; Toshihiro Kumabe; Masayuki Kanamori; Yukihiko Sonoda; Mika Watanabe; Teiji Tominaga
Journal:  Neurosurg Rev       Date:  2011-02-08       Impact factor: 3.042

5.  Gliomatosis cerebri: clinical characteristics, management, and outcomes.

Authors:  Selby Chen; Shota Tanaka; Caterina Giannini; Jonathan Morris; Elizabeth S Yan; Jan Buckner; Daniel H Lachance; Ian F Parney
Journal:  J Neurooncol       Date:  2013-01-23       Impact factor: 4.130

6.  AJAP1 expression modulates glioma cell motility and correlates with tumor growth and survival.

Authors:  Chunhui Di; Nikol Mladkova; James Lin; Brian Fee; Miriam Rivas; Kang Chunsheng; Darell Bigner; David Cory Adamson
Journal:  Int J Oncol       Date:  2017-11-01       Impact factor: 5.650

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.